Article Text

PDF
▼ Fidaxomicin for the treatment of Clostridium difficile infections

Abstract

Clostridium difficile infection (CDI), also known as C. difficile-associated disease or diarrhoea (CDAD), is an important cause of hospital-acquired diarrhoea with disease severity ranging from mild diarrhoea to fulminant colitis.1,2 In addition, over 40% of new cases of CDI occur outside hospital.3,4 ▼ Fidaxomicin (Dificlir – Astellas), the first antibiotic in a new class called macrocyclics, has recently been licensed for the treatment of C. difficile infection in adults.5 Here we provide a brief overview of C. difficile infection and assess how fidaxomicin fits with current management strategies for treatment of such infections.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.